• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»EGFR L858R

Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate

By Pallavi Madhiraju on April 21, 2026   Pharma & Biotech  

Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate

Lantern Pharma’s LP-300 showed an early EGFR L858R lung cancer signal. Read what the FDA meeting and trial redesign could change next.

Recent Posts

  • Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?
  • FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
  • Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate
  • Can Hologic’s breast imaging AI close one of mammography’s most stubborn detection gaps?
  • Takara Bio USA unveils AACR benchmark data for Trekker FX, but will cancer labs switch?
  • Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?
  • Could Entos Pharmaceuticals’ Fusogenix platform open a real path to treatment in L-CMD?
  • What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
  • Can Debiopharm turn a Fast Track win into a real ovarian cancer breakthrough?
  • Why Dana-Farber’s Enhertu biomarker study could change metastatic breast cancer diagnostics
  • Why CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy strategies
  • Akari Therapeutics Plc advances AKTX-101 as RNA splicing ADC targets TROP2 resistance in oncology
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes